Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy.
Prognostic markers for nodal metastasis in thin melanoma patients are debated. We present a single institution study looking at factors predictive of nodal disease in thin melanoma patients. Retrospective review from 1997 to 2012 identified 252 patients with thin melanoma (≤1 mm) who underwent a sentinel lymph node biopsy (SLNB). Node-positive patients included positive SLNB patients and negative SLNB patients who developed a nodal recurrence (false-negative SLNB). Clinicopathologic characteristics were correlated with nodal status and outcome. Median follow-up was 45.5 months. Twelve of 252 patients (4.8%) were node-positive including six positive SLNB (2.4%) and six false-negative SLNB (2.4%) patients. No clinicopathologic factors were significantly correlated with nodal disease. For the six false-negative SLNB patients, median time to nodal recurrence was 37.5 months. Regression was seen in only 16% of cases, but the rate increased to 60% for false-negative SLNB cases. Both age (odds ratio [OR]: 1.09, 95% CI: 1.01-1.17; P = 0.02) and regression (OR: 8.33, 95% CI: 1.34-52.63; P = 0.02) were significantly associated with nodal recurrence after a negative SLNB on univariable analysis. Nodal disease in thin melanoma patients was seen in 4.8% of cases. Although regression was not correlated with nodal metastasis, it was correlated with a false-negative SLNB. Patients with thin melanoma and regression may need more intensive surveillance after a negative SLNB. Further study is needed to determine if the same immune mechanisms that result in regression in primary tumors also lead to regression in lymph nodes, which may decrease detection of melanoma nodal metastases.
Section of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, 06520.
Jill C
JC
Rubinstein
Department of Epidemiology & Biostatistics, Texas A&M, College Station, Texas, 77843.
Gang
G
Han
Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, 06520.
Laura
L
Jackson
Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, 06520.
Kaleigh
K
Bulloch
Section of Plastic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, 06520.
Stephan
S
Ariyan
Section of Plastic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, 06520.
Deepak
D
Narayan
Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, 06520.
Bonnie G
BG
Rothberg
Section of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, 06520. dale.han@yale.edu.
Dale
D
Han
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D011379:Prognosis; D012189:Retrospective Studies; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
Nodal recurrence; regression; sentinel lymph node biopsy; thin melanoma
JAMA Dermatol. 2014 Aug;150(8):828-35
24898614
Semin Surg Oncol. 1993 May-Jun;9(3):219-23
8516607
Am J Surg Pathol. 2013 Dec;37(12):1797-814
24061524
Ann Surg. 1988 Aug;208(2):150-61
3401060
J Clin Oncol. 2011 Apr 10;29(11):1479-87
21383281
J Clin Oncol. 2006 Sep 20;24(27):4464-71
16983115
Ann Surg Oncol. 2012 Oct;19(11):3313-24
22766987
J Natl Compr Canc Netw. 2016 Apr;14(4):450-73
27059193
N Engl J Med. 2014 Feb 13;370(7):599-609
24521106
Ann Surg Oncol. 2008 Jan;15(1):316-22
18004626
J Clin Oncol. 2009 Dec 20;27(36):6199-206
19917835
J Clin Oncol. 2013 Dec 10;31(35):4387-93
24190111
Cancer Med. 2016 Oct;5(10):2832-2840
27671840
Arch Surg. 2008 Sep;143(9):892-9; discussion 899-900
18794428
Ann Surg Oncol. 2016 Mar;23(3):1012-8
26586498
Cancer. 1985 Nov 1;56(9):2287-91
4052972
Am J Surg. 2011 Mar;201(3):324-7; discussion 327-8
21367372
Am J Dermatopathol. 2003 Oct;25(5):371-6
14501285
Ann Surg. 2003 Oct;238(4):528-35; discussion 535-7
14530724
Ann Surg Oncol. 2012 Oct;19(11):3335-42
22766986
JAMA Surg. 2013 May;148(5):456-61
23325294
Q J Nucl Med Mol Imaging. 2014 Jun;58(2):105-13
24835287
Am Soc Clin Oncol Educ Book. 2013;:
23714536
Ann Surg Oncol. 2016 Dec;23(13):4178-4188
26932710
Ann Surg Oncol. 2009 Jun;16(6):1548-52
19277787
Cancer. 2003 Sep 15;98(6):1223-31
12973846
J Invest Dermatol. 2009 Jul;129(7):1666-74
19131946
Ann Surg Oncol. 2010 Mar;17(3):670-3
19953329
Arch Surg. 2010 Feb;145(2):137-42
20157080
J Clin Oncol. 2012 Aug 10;30(23):2912-8
22778321
J Natl Compr Canc Netw. 2009 Mar;7(3):308-17
19401063
Ann Surg Oncol. 2010 Mar;17(3):709-17
19967459
J Clin Oncol. 2004 Sep 15;22(18):3668-76
15302909
Arch Surg. 1992 Apr;127(4):392-9
1558490
Am J Surg. 2002 Dec;184(6):520-4; discussion 525
12488154
Ann Surg Oncol. 2003 Jan-Feb;10(1):21-6
12513955
Br J Dermatol. 2003 Sep;149(3):662-3
14511013